Xu Stella 4
4 · NextCure, Inc. · Filed May 13, 2019
Insider Transaction Report
Form 4
NextCure, Inc.NXTC
Xu Stella
Director
Transactions
- Conversion
Common Stock
2019-05-13+978,570→ 978,570 total(indirect: By Quan Venture Fund II, L.P.) - Purchase
Common Stock
2019-05-13$15.00/sh+125,000$1,875,000→ 1,103,570 total(indirect: By Quan Venture Fund II, L.P.) - Conversion
Series B-2 Preferred Stock
2019-05-13−7,861,636→ 0 total(indirect: By Quan Venture Fund II, L.P.)→ Common Stock (978,570 underlying)
Footnotes (2)
- [F1]The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P. except to the extent of her pecuniary interest therein.